FDG and NaF PET/CT Predictive for Overall Survival in Genitourinary Malignancies
February 19th 2022At 2022 ASCO GU, early trial results show promise for fluorodeoxyglucose and sodium fluoride PET/CT prognostic ability to predict survival in patients with metastatic genitourinary malignancies treated with cabozantinib plus PD-1/CTLA-3 inhibition.